zm-02
Gene therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 25, 2024 (NCT06292650)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Alpha-synucleinSupplementation
SNCA supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07282457 | Phase 1/Phase 2 (Phase 2) | Feb 25, 2026 | Government of China |
| NCT06292650 | Early Phase 1 (Phase 1) | Feb 25, 2024 | Capital Medical University, Government of China |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 2 | 2 | 2 | 2024 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1